Fate Therapeutics to Present at Upcoming Investor Conferences

Core Viewpoint - Fate Therapeutics, Inc. is focused on developing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies for cancer and autoimmune diseases [2] Company Overview - Fate Therapeutics is a clinical-stage biopharmaceutical company headquartered in San Diego, CA, specializing in iPSC-derived cellular immunotherapies [2] - The company has established a leadership position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products [2] - The pipeline includes iPSC-derived natural killer (NK) cell and T-cell product candidates designed with novel synthetic controls to deliver multiple therapeutic mechanisms [2] Upcoming Events - The company will participate in several investor conferences, including: - H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference on February 25, 2025, with a fireside chat at 1:30 PM ET [3] - TD Cowen 45th Annual Health Care Conference on March 3, 2025, with a presentation at 11:50 AM ET in Boston, Massachusetts [3] - Barclays 27th Annual Global Healthcare Conference on March 11, 2025, with a fireside chat at 8:30 AM ET in Miami, Florida [3] - Leerink Partners Global Healthcare Conference on March 12, 2025, with a fireside chat at 11:20 AM ET in Miami, Florida [3]